In this episode, “CAR T-cell Therapy Production & Treatment: Regionalized POC vs. Centralized Manufacturing,” join Christopher Montalbano, CEO of MIDI, navigates the evolving landscape of CAR T-Cell Therapy manufacturing, exploring its profound impact on patient treatment. Discover the transformative shift from traditional centralized production to the innovative Point-of-Care (POC) manufacturing approach.
What You’ll Learn:
- Centralized Manufacturing Workflow: Understand the current process for autologous CAR T-Cell Therapy, including T-cell collection, transportation to centralized labs for genetic engineering and cell expansion, and reinfusion into patients. Chris highlights both the advantages and the significant challenges, such as limited access, high costs, and the need for specialized facilities.
- Critical Challenges: Uncover the issues with centralized manufacturing, including manufacturing constraints, labor-intensive processes, high costs, and the logistical complexities that limit accessibility and scalability.
- Point-of-Care Manufacturing: Explore the paradigm shift to POC manufacturing, which brings production directly to the patient's care site. Learn how this approach can revolutionize CAR T-Cell Therapy by enabling commercial-scale production, reducing costs, shortening timelines, minimizing contamination risks, and preserving cell quality.
Why Tune In?
Join us as we delve into the future of CAR T-Cell Therapy manufacturing, where POC methods promise to democratize this groundbreaking treatment. Whether you're a healthcare professional, researcher, or patient, this episode provides crucial insights into how decentralized manufacturing can make CAR T-Cell Therapy more accessible, efficient, and affordable.
Stay Informed and Inspired.
Tune in to discover how Point-of-Care manufacturing is set to transform the landscape of CAR T-Cell Therapy, paving the way for more equitable and effective cancer treatments. Stay at the forefront of medical innovation with us!